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Background: Soil-transmitted helminth (STH) infections are responsible for a huge public health burden, however
treatment options are limited. The discovery and development of novel efficacious drugs or drug combinations for
the treatment of STH infections therefore has a high research priority.
Methods: We studied drug combination effects using the main standard anthelmintics, albendazole, mebendazole,
levamisole, pyrantel pamoate and ivermectin in the Trichuris muris model. Drug combinations were first tested
in vitro and additive and synergistic combinations investigated further in vivo in female mice using ratios based on
the ED50 of the respective drugs.
Results: In vitro all 10 combinations of the standard anthelmintics tested against T. muris revealed synergistic
behavior. We identified three drug combinations in vivo as strongly synergistic, namely mebendazole-ivermectin
(Combination index (CI)=0.16), mebendazole-levamisole (CI=0.17) and albendazole-mebendazole (CI=0.23). For
albendazole-ivermectin, moderate synergism was observed (CI=0.81) and for albendazole-levamisole a nearly
additive effect was documented (CI=0.93) in vivo. Five combinations (albendazole-pyrantel pamoate,
mebendazole-pyrantel pamoate, levamisole-pyrantel pamoate, levamisole-ivermectin and pyrantel pamoate-
ivermectin) were antagonistic in vivo.
Conclusion: Our results strengthen the evidence that combination chemotherapy might play a role in the
treatment of Trichuris infections. Albendazole-mebendazole should be studied in greater detail in preclinical studies.
Keywords: Combination chemotherapy, Trichuris muris, Albendazole, Mebendazole, Pyrantel pamoate, Ivermectin,
Levamisole, In vitro, In vivoBackground
Soil-transmitted helminth (STH) infections impose a
major public health burden mostly among poor popula-
tions. It has been estimated that in 2010, 5.3 billion
people, of these 1.0 billion school-aged children, were at
risk of infection with at least one STH species [1]. Pre-
ventive chemotherapy, with the two benzimidazoles,
albendazole and mebendazole forms the bedrock of hel-
minth control initiatives preventing morbidity due to
helminthiases [2]. However, the number of drugs used to
treat infections with STH are limited, have only a low* Correspondence: jennifer.keiser@unibas.ch
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reproduction in any medium, provided the orefficacy against Trichuris trichiura as a single dose treat-
ment and there is a potential for the development of
drug resistance [3,4]. Therefore, recently the Disease
Reference Group on Helminth Infections established by
the Special Programme for Research and Training in
Tropical Diseases (TDR) was given the mandate to de-
velop a research and development agenda for interven-
tion tools considered necessary for control and
elimination of human helminthiases [5]. The discovery
and development of novel efficacious drugs was identi-
fied as one of the top research priorities [6]. In addition,
it has been emphasized that more research should be
undertaken to investigate whether combinations of dif-
ferent anthelmintics would reveal synergistic effects and
would therefore improve control of helminth infectionstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Activity of combinations of standard anthelmintics
against T. muris in vitro, expressed as IC50 values and
combination indices (CI)
Drug activity against T. muris adult worms in vitro
Single drug IC50s (μg/ml) (r)
Albendazole > 200 (0.40)§
Mebendazole > 200 (0.58)
Levamisole 16.5 (1.0)§
Pyrantel pamoate 34.1 (0.99)§
Ivermectin > 200 (0.40)
Drug combination CI at IC50
Albendazole-mebendazole < 0.001
Albendazole-levamisole 0.12
Albendazole-pyrantel pamoate 0.11
Albendazole-ivermectin < 0.001
Mebendazole-levamisole 0.04
Mebendazole-pyrantel pamoate 0.12
Mebendazole-ivermectin < 0.001
Levamisole-pyrantel pamoate 0.007
Levamisole-ivermectin 0.12
Pyrantel pamoate-ivermectin 0.14
IC50 median inhibitory concentration. r = linear correlation coefficient of the
median-effect plot, indicating the goodness of fit. r ≥ 0.85 indicates a satisfactory fit.
§ IC50s of albendazole, levamisole, and pyrantel pamoate have been published
elsewhere [13].
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assess whether combinations of different anthelmintics
produce synergistic effects. We have recently studied the
effects of oxantel pamoate in combination with standard
drugs albendazole, mebendazole, pyrantel pamoate, lev-
amisole and ivermectin against T. muris in vitro and
in vivo (Keiser et al., submitted for publication). Using
Caenorhabditis elegans, significant synergy was docu-
mented between Cry proteins from Bacillus thuringiensis
and tribendimidine or levamisole [7]. Similarly, tribendi-
midine combined with levamisole showed synergistic
effects against Ancylostoma ceylanicum in vitro and
in vivo in male Syrian Golden hamsters [8]. Several clin-
ical trials have also been conducted with drug combinations
in patients infected with hookworms or T. trichiura
[4,9-11], however, the scientific basis for selecting these
combinations is not clear. Prior to clinical trials, drug com-
bination studies in vitro and/or in animal models followed
by preclinical drug interaction studies should be carried out
to determine the basis and rationale for studies in humans
and to confirm that concomitant use of the medications is
safe.
The aim of the present study was to analyze drug com-
bination effects using the main standard anthelmintics
albendazole, mebendazole, levamisole, pyrantel pamoate
and ivermectin in the T. muris mouse model. Drug combi-
nations were first tested in vitro and additive and synergis-
tic combinations further investigated in vivo.
Methods
Drugs
Albendazole and levamisole were purchased from Fluka
(Buchs, Switzerland). Mebendazole, ivermectin and pyran-
tel pamoate were acquired from Sigma-Aldrich (Buchs,
Switzerland). Drug stock solutions of 10 mg/ml were pre-
pared in 100% DMSO (Sigma-Aldrich, Buchs, Switzerland)
for in vitro studies. These were stored at 4°C pending use.
For in vivo treatments, the drugs were suspended in 10%
Tween 80 [70% EtOH (70:30 v/v)] (Buchs, Switzerland)
and 90% deionised H2O just prior to oral administration.
Ethics statement
Experiments were performed in accordance with the 3R
rules for animal experiments. The current study was
approved by the cantonal veterinary office Basel-Stadt
(Switzerland) based on Swiss cantonal and national reg-
ulations (permission no. 2070).
Animals and infections
Four week-old female C57BL/10 mice were purchased
from Harlan (Blackthorn, UK). Before infection, animals
were acclimatized for one week in the animal facility.
Groups of 10 mice were kept in macrolon cages with ad
libitum access to water and rodent food (Rodent Bloxfrom Eberle NAFAG, Gossau, Switzerland). The T. muris
life-cycle and maintenance have been described else-
where [12,13]. Briefly, mice were treated with 1 mg/l
dexamethasone (dexamethasone-water soluble, Sigma-
Aldrich) supplied in the drinking water 2 days before in-
fection by oral gavage with 200 embryonated T. muris
eggs until 2 days preceding treatment. Adult worms
were recovered from the intestines of sacrificed animals
from day 35 p.i. onwards (binocular, magnification 16x)
and kept at 37°C, 5% CO2, in RPMI medium [10.44 g
RPMI 1640 (Gibco, Basel, Switzerland) 5 g albumax H
(Gibco), 5.94 g HEPES (Sigma-Aldrich) and 2.1 g so-
dium bicarbonate (Sigma-Aldrich) in 1 l dH2O] supple-
mented with 5% v/v amphotericin B (stock: 250 μg/ml,
Sigma-Aldrich) and 1% v/v penicillin-streptomycin
(stock: 10,000 U/ml penicillin + 10 mg/ml streptomycin,
Sigma-Aldrich).
In vitro drug combination studies
Two adult worms were incubated in each well of a 48-
well plate containing 500 μl pre-warmed supplemented
RPMI medium (described above), and 500 μl drug solu-
tion. IC50 (50% inhibitory concentration) values of the
standard drugs were determined in our laboratory prior
to this work and are summarized in Table 1. In more de-
tail, for levamisole and pyrantel pamoate, IC50s of 16.5
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drugs on the worms was observed at the highest concen-
tration tested as for albendazole, mebendazole and iver-
mectin, IC50 values of 200 μg/ml were chosen arbitrarily
for the drug combination studies presented here. Six
concentrations of each drug concentration were tested,
starting with the IC50 value of each partner drug
(IC50+IC50), which was two-fold diluted up to a final con-
centration of 1/32IC50+1/32IC50. Control worms were
incubated in medium with equivalent DMSO concentra-
tions (maximum 4% v/v). The plate was incubated at
37°C and 5% CO2. After 72 h the motility was evaluated
under a light microscope (magnification 20-80x) using a
motility scale from 0 to 3 (0 = dead, 1 = very low motility,
2 = low motility, 3 = normal motility) as described previ-
ously [13]. Experiments were carried out in duplicate and
repeated at least twice. Data obtained from the individual
experiments were averaged and adjusted to the values
obtained from untreated controls. The nature of each drug
combination was characterized by a combination index
(CI) as described by Chou [14] and calculated with
CompuSyn (CompuSyn, version 3.0.1, ComboSyn, Inc.,
Paramus, NJ 2007). We used the following classification
CI<0.1 very strong synergism, CI: 0.1-0.3 strong
synergism, CI: 0.3-0.7 synergism, CI: 0.7-0.85 moderate
synergism, CI: 0.85-0.9 slight synergism, CI: 0.9-1.1 nearly
additive and CI>1.1 antagonism. Synergistic and additive
drug combinations identified in vitro (CI≤1) were tested
in infected animals using a constant dose ratio as described
below.
In vivo drug combination studies
On day 40 post-infection the presence of a chronic
T. muris infection was confirmed in each mouse by
an egg positive stool examination. Groups of 4 mice were
assigned to treatment or served as untreated control. ED50s
(median effective doses) of each standard drug had been
determined in our laboratory prior to this work and were
as follows; 345 mg/kg for albendazole, 79 mg/kg for
mebendazole (Keiser et al., submitted for publication), 46
mg/kg for levamisole and 4 mg/kg for ivermectin [15]. An
arbitrary value of 300 mg/kg was chosen for pyrantel pamo-
ate, for which no ED50 could be calculated. The ratio of the
ED50s of each partner drug was chosen as starting dose
(drug 1 ED50+ drug 2 ED50). If a combination treatment
decreased the worm burden by at least 75% (threshold for
additivity when the dose effect curves for both drugs are
hyperbolic [14]), the drug doses were reduced by half.
Stools were collected for up to 72 h post-treatment and the
expelled worms were counted. Mice were killed one week
post-treatment by exposure to CO2, the entire intestine was
dissected and all remaining worms counted. Drug activity
was expressed by worm burden reduction (WBR) and
worm expulsion rate (WER) as described elsewhere [8].The significance of the WBR was tested using the Kruskal-
Wallis test (several treatment doses vs. controls) or the
Mann–Whitney U-test (one treatment dose vs. control)
using StatsDirect (version 2.4.5; StatsDirect Ltd; Cheshire,
UK). Combination indices (CI) were calculated with Com-
puSyn as described above.
Results
Activity of combinations of standard anthelmintics
against T. muris in vitro
All 10 combinations of the standard anthelmintics tested
against T. muris in vitro resulted in a synergistic inter-
action (Table 1). A very strong synergism (CI<0.1) was
observed for albendazole-mebendazole, albendazole-
ivermectin and mebendazole-ivermectin (all CIs<0.001),
mebendazole-levamisole (CI=0.04) and levamisole-pyrantel
pamoate (CI=0.007). For the other 5 combinations
(albendazole-levamisole, albendazole-pyrantel pamo-
ate, mebendazole-pyrantel pamoate, levamisole-ivermectin
and pyrantel pamoate-ivermectin a strong synergism
(CI=0.11-0.14) was determined.
Activity of combinations of standard anthelmintics
against T. muris in vivo
Since all anthelmintic drug combinations yielded synergistic
effects in vitro, they were further investigated in vivo using
the ED50 of each drug (drug 1 ED50 + drug 2 ED50) as start-
ing dose. The results are summarized in Table 2. We identi-
fied three drug combinations as strongly synergistic, namely
mebendazole-ivermectin (CI=0.16), mebendazole-levamisole
(CI=0.17) and albendazole-mebendazole (CI=0.23). These
drug combinations still achieved significant WBRs when
drug dosages of 1/16 ED50 were combined. For example, a
WBR of 70.3% was achieved, when 4.9 mg/kg mebendazole
was combined with 0.25 mg/kg ivermectin. Note that
mebendazole plus ivermectin (at the highest dose) was the
only combination that resulted in complete elimination of
worms.
For albendazole plus ivermectin a moderate synergism
was observed (CI=0.81) and when albendazole was
administered together with levamisole a nearly additive
effect was documented (CI=0.93).
Five combinations (albendazole-pyrantel pamoate,
mebendazole-pyrantel pamoate, levamisole-pyrantel
pamoate, levamisole-ivermectin and pyrantel pamoate-
ivermectin) revealed an antagonistic behavior. Four of
these drug combinations (mebendazole-pyrantel pamo-
ate, levamisole-pyrantel pamoate, levamisole-ivermectin
and pyrantel pamoate-ivermectin) showed an effect at
the highest dosage tested (ED50+ED50) with WBRs of
79.7-96.8% but only low activity when half of these
dosages were used. Albendazole-pyrantel pamoate
(ED50+ED50) resulted in only a moderate worm burden
reduction of 44.2%.
Table 2 Worm expulsion rates, worm burden reductions and corresponding combination index values obtained
following treatment of mice harboring adult T. muris with combinations of standard anthelmintics
Group Dose (mg/kg) Mean number of
worms (SD)
Mean number of
expelled worms (SD)
Worm expulsion
rate (%)
Worm burden
reduction (%)
P-value Combination
index at ED50
Control 1 – 93.25 (9.46) 0.75 (0.96) 0.8 – – –
Control 2 – 123.25 (35.07) 0.25 (0.50) 0.2 – – –
Control 3 – 91.25 (23.73) 0 (0) 0 – – –
Control 4 – 78.33 (20.79) 0 (0) 0 – – –
Control 5 – 85.71 (21.75) 0 (0) 0 – – –
Control 6 – 82.57 (30.59) 0 (0) 0 – – –
Control 7 – 94.4 (39.21) 0 (0) 0 – – –
Control 8 – 56.50 (22.07) 0 (0) 0 – – –
ABZ-MBZ 345+793 77.50 (63.07) 60.50 (55.87) 78.06 81.37 <0.001a 0.23
172.5+39.54 73.25 (102.66) 62.75 (91.34) 85.67 86.60
86.25+19.757 95.0 (5.66) 63.0 (1.41) 66.32 66.10
43.125+ 9.8758 77.75 (33.54) 47.75 (22.34) 61.41 46.90
ABZ-LEV 345+465 117.50 (112.86) 107.0 (112.75) 91.06 87.75 0.001a 0.93
172.5+237 89.25 (42.0) 46.50 (35.61) 52.10 54.71
ABZ-PYR 345+3004 63.5 (41.30) 19.75 (11.76) 31.10 44.15 0.229b –
ABZ-IVM 345+42 136.50 (14.98) 109.50 (15.76) 80.22 78.05 0.003a 0.81
172.5+27 80.50 (17.06) 41.50 (9.26) 51.55 58.69
MBZ-LEV 79+461 86.0 (53.20) 82.75 (48.11) 96.22 96.49 <0.001a 0.17
39.5+232 82.0 (17.87) 74.5 (21.32) 90.85 93.90
19.75+12.53 96.25 (37.25) 81.25 (39.10) 84.42 83.56
9.875+6.254 61.25 (33.98) 50.50 (37.36) 82.45 86.28
4.94+3.1257 125.50 (71.01) 48.75 (37.55) 38.84 18.70
MBZ-PYR 79+3004 41.25 (24.65) 38.75 (24.92) 93.94 96.81 0.049a N.D.
39.5+1508 161.75 (98.22) 113.75 (77.82) 70.32 15.04
MBZ-IVM 79+42 92.50 (26.71) 92.50 (26.71) 100 100 <0.001a 0.16
39.5+22 70.33 (32.04) 68.0 (32.19) 96.68 98.10
19.75+13 46.25 (18.23) 36.75 (11.53) 79.46 89.59
9.875+0.54 54.0 (44.74) 41.50 (36.74) 76.85 84.04
4.94+0.257 101.0 (57.30) 73.0 (34.70) 72.28 70.34
2.47+0.1258 70.33 (26.86) 16.67 (22.85) 23.70 5.01
LEV-PYR 46+3006 46.25 (18.84) 29.50 (19.28) 63.78 79.71 0.057a N.D.
23+1508 87.75 (57.34) 10.50 (10.88) 11.97 0
LEV-IVM 46+44 66.25 (42.84) 59.0 (42.78) 89.06 90.74 0.009a 1.38
23+28 60.0 (24.51) 14.50 (13.80) 24.17 19.47
PYR-IVM 300+44 52.25 (36.04) 46.75 (32.71) 89.47 92.98 0.032a N.D.
150+28 122.50 (112.38) 32.75 (17.39) 26.73 0
Numbers in superscript refer to the corresponding control group. aP-values were obtained from the Kruskal-Wallis test (several treatment doses vs. controls), bP-
values were obtained from the Mann–Whitney U test (one treatment dose vs. controls). The CI at ED50 are based on worm burden reductions. N.D. = not
determined. ABZ: albendazole; MBZ: mebendazole; LEV: levamisole; PYR: pyrantel pamoate; IVM: ivermectin.
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The treatment of T. trichiura infections in humans has
significant deficiencies, since none of the available
anthelmintics achieves high cure rates and egg reduction
rates, when the drugs are administered as single doses inthe framework of preventive chemotherapy treatment
campaigns [2,3]. Combination chemotherapy is common
medical practice in several medical fields such as cancer,
bacterial infections, HIV or malaria [4,16,17] as well as in
veterinary medicine [18] since an efficacious intervention
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acting therapeutic components. Furthermore, avoiding
drug resistance has been a major rationale for combin-
ation chemotherapy from the start [16,17].
To the best of our knowledge, we have for the first time
thoroughly evaluated the activity of combinations of avail-
able marketed human anthelmintics against the laboratory
model T. muris in vitro and in vivo. In vitro, all combina-
tions were found to be synergistic (Figure 1) and thereforeFigure 1 Study flow diagram, illustrating the results of our studies
2 Reference [22], 3 Reference [11], 4 Reference [24], 5 Reference [25], 6 Refollowed up in vivo. Four drug combinations were identified
in vivo using drug doses based on ED50 values, which
showed synergistic properties namely mebendazole-ivermec-
tin, mebendazole-levamisole, albendazole-mebendazole and
albendazole plus ivermectin. In addition, for the combin-
ation of albendazole and levamisole an additive trichuricidal
effect was documented (Figure 1). A good correlation be-
tween the in vitro and in vivo results was observed with the
3 drug combinations showing a strongly synergistic effectand placing them in context with clinical trials. 1: Reference [10],
ference [26], 7 Reference [27]. ERR: egg reduction rate; CR: cure rate.
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and mebendazole-ivermectin) also revealing synergism
in vivo. It is interesting to note that the synergistic combina-
tions identified comprise at least one benzimidazole. Drug
combinations containing pyrantel pamoate as well as lev-
amisole combined with ivermectin were found to be antag-
onistic. An increased bioavailability of ivermectin was
observed when the drug was given concurrently with lev-
amisole in healthy volunteers [19], however, it is not clear
whether this pharmacokinetic interaction has an influence
on the activity against T. muris in mice. Unfortunately, pos-
sible mechanisms underlying synergistic or antagonistic
effects are presently not available for any of these anthelmin-
tic drug combinations. It has recently been suggested that
an increased efficacy of an albendazole-mebendazole com-
bination over albendazole or mebendazole monotherapy
might be explained by an extended contact period of the
worms with the active compounds (active compounds
present successively: mebendazole first followed by the main
metabolite of albendazole, albendazole sulfoxide [11]). How-
ever, it has been suggested that the parent drug albendazole,
more lipophilic, exerts the main anthelmintic action as the
transcuticular diffusion is thought to be more important for
drug uptake by worms [20,21], which would contradict
the above mentioned hypothesis of an increased activ-
ity due to albendazole sulfoxide.
Clinical trials have been conducted with the four syn-
ergistic combinations reported here (Figure 1). Ironically
these trials have been conducted without any preclinical
supporting information, either on efficacy or potential
toxicity. No enhanced trichuricidal efficacy was
observed when a combination of mebendazole and lev-
amisole was given to school-aged children on Pemba
island [22]. However, our findings of the synergistic effect
of albendazole-ivermectin, mebendazole-ivermectin and
albendazole-mebendazole in T. muris-infected mice are in
line with results from patients infected with T. trichiura.
Briefly, five studies investigated the efficacy of albendazole-
ivermectin [10,23-26] and increased cure rates and egg re-
duction rates for the combination compared to albendazole
or ivermectin were observed in all trials. Clearly, a tremen-
dous advantage of an albendazole-ivermectin combination
is its broad spectrum of activity targeting not only the soil-
transmitted helminths, including Strongyloides stercoralis
but also lymphatic filariasis and onchocerciasis. In three of
the trials the effect of albendazole-ivermectin was also
assessed against infections with hookworms, however, no
increased therapeutic benefit was observed for albendazole-
ivermectin over albendazole [10,22,24]. Moreover, the com-
bination has already been studied in onchocerciasis patients
and no pharmacokinetic interactions were observed [19].
Mebendazole-ivermectin showed an even superior activity
to albendazole-ivermectin [10], which might be explained
by the higher sensitivity of Trichuris spp. to mebendazolethan albendazole. However, it is important to mention that
the combination of mebendazole and ivermectin only
achieved moderate egg reduction rates and low cure rates
against hookworm infections [10]. Finally, albendazole-
mebendazole achieved a higher cure rate (46.1%) compared
to albendazole (6.0%) and mebendazole (11%) in school-
aged children infected with T. trichiura in Uganda [11].
In the present work an additive effect was observed
when levamisole was administered in combination with
albendazole to T. muris-infected mice. To our know-
ledge, this combination has not been used in the treat-
ment of trichuriasis. However, Awadzi and colleagues
have shown that clinically significant drug interactions
occur between the two drugs, resulting in a reduction of
albendazole sulfoxide and levamisole plasma levels as
well as unexpected adverse events in onchocerciasis
patients [27]. Hence, given these pharmacokinetic inter-
actions a simultaneous co-administration of albendazole
and levamisole cannot be recommended.Conclusions
We have identified four synergistic and one additive
combination against T. muris in the mouse model. To
shed light on the next steps to be undertaken we have
placed our findings in context with Phase I and Phase II
clinical trials conducted with these drug combinations in
previous years. In addition, it has to be emphasized that
the four species of nematodes (Ascaris lumbricoides,
T. trichiura and both hookworm species, Ancylostoma
duodenale and Necator americanus) are treated collectively
in preventive chemotherapy programs and the treatments
should therefore have high activities against all these spe-
cies. Albendazole-mebendazole has emerged as an interest-
ing and unexpected drug combination, hence this
treatment should be studied in greater detail including drug
interaction studies as well as studies against hookworms. In
addition, albendazole-ivermectin offers the advantage that
it is well studied, has increased trichuricidal activity over
albendazole and ivermectin alone and has a broad
spectrum of activity.
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